<DOC>
	<DOCNO>NCT00422942</DOCNO>
	<brief_summary>This single arm study investigate pattern B cell depletion synovial tissue peripheral blood patient active RA , MabThera ( 1000mg iv x 2 day 1 15 ) + methotrexate ( 10-25mg/week po ) treatment . The clinical efficacy pharmacokinetic profile MabThera treatment retreatment also investigate . The anticipated time study treatment 2+ year , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Pharmacokinetic Pharmacodynamic Study MabThera ( Rituximab ) Plus Methotrexate Patients With Rheumatoid Arthritis ( RA )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>adult patient 1880 year age ; RA &gt; =3 month ; receive outpatient treatment ; fail treatment &gt; =1 DMARD ( anti TNF biologic therapy ) ; inadequate response methotrexate , take tolerated &gt; =12 week , stable dose &gt; =4 week . rheumatic autoimmune disease RA , significant systemic involvement secondary RA ; history , current , inflammatory joint disease RA , systemic autoimmune disorder ; diagnosis RA age 16 ; bone/joint surgery within 12 week study ; prior use antiTNF biologic therapy , antialpha 4 integrin , celldepleting therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>